OmniAb, Inc. OABI
OmniAb, Inc. licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners' drug development efforts. At the heart of the OmniAb platform is what we call Biological IntelligenceTM, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns our interests with the scientific and economic interests of our partners through structured platform license agreements that generally include upfront or annual access fees, service revenue, milestones and royalties on commercial sales.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $18.7M | $26.4M | $34.2M | $59.1M | $34.7M | — |
| R&D | $47.8M | $55.1M | $56.5M | $48.4M | $39.2M | — |
| SG&A | $29.2M | $30.7M | $33.3M | $24.9M | $16.9M | — |
| Total operating expenses | $87.6M | $100.9M | $103.6M | $85.7M | $70.4M | — |
| Operating income | -$69.0M | -$74.5M | -$69.4M | -$26.6M | -$35.6M | — |
| Interest expense | — | — | — | $0 | $7.0K | — |
| Pre-tax income | -$66.3M | -$71.4M | -$64.4M | -$26.1M | -$34.4M | — |
| Income tax | $1.5M | $9.4M | $13.7M | $3.7M | $7.3M | — |
| Net income | -$64.8M | -$62.0M | -$50.6M | -$22.3M | -$27.0M | — |
| EPS, basic | -0.57 | -0.61 | -0.51 | -0.26 | -0.33 | — |
| EPS, diluted | -0.57 | -0.61 | -0.51 | -0.26 | -0.33 | — |
| Shares, diluted (wtd. avg.) | 113.6M | 102.4M | 99.7M | 82.6M | 82.6M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $25.5M | $27.6M | $16.9M | $33.8M | $0 | $0 |
| Short-term investments | $28.5M | $31.8M | $70.6M | $54.9M | $0 | — |
| Receivables | $7.4M | $5.3M | $3.8M | $30.3M | $21.1M | — |
| Inventory | $823.0K | $48.0K | — | — | — | — |
| Total current assets | $65.3M | $68.1M | $94.9M | $100.3M | $22.5M | — |
| Property, plant and equipment | $9.4M | $15.5M | $18.2M | $19.9M | $6.8M | — |
| Goodwill | $84.0M | $84.0M | $84.0M | $84.0M | $84.0M | — |
| Other intangibles | $125.1M | $138.1M | $155.5M | $166.2M | $176.3M | — |
| Total assets | $300.9M | $325.6M | $375.2M | $393.1M | $304.5M | — |
| Accounts payable | $1.9M | $2.3M | $4.4M | $473.0K | $2.9M | — |
| Total current liabilities | $16.3M | $15.1M | $23.1M | $12.3M | $20.6M | — |
| Total liabilities | $33.9M | $37.9M | $60.6M | $67.1M | $70.2M | — |
| Retained earnings | -$166.2M | -$101.4M | -$39.4M | $11.3M | $0 | — |
| Total equity | $267.0M | $287.6M | $314.6M | $341.4M | $234.3M | $235.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$36.5M | -$39.7M | $2.3M | -$3.6M | -$5.7M | — |
| Depreciation and amortisation | $21.8M | $23.6M | $19.5M | $18.2M | $16.3M | — |
| Stock-based compensation | $15.8M | $21.5M | $24.8M | $18.3M | $15.1M | — |
| Capital expenditure | $565.0K | $1.9M | $1.6M | $17.2M | $4.1M | — |
| Investing cash flow | $6.5M | $37.9M | -$18.4M | -$73.3M | -$4.0M | — |
| Financing cash flow | $27.9M | $13.0M | -$892.0K | $110.7M | $9.7M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001846253-26-000009.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $34.7M | $59.1M | $34.2M | $26.4M | $18.7M |
| Gross profit | — | — | — | — | — | — |
| Net income | — | -$27.0M | -$22.3M | -$50.6M | -$62.0M | -$64.8M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8731
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IQV | IQVIA HOLDINGS INC. | $46.63B | 35.6x | 5.9% |
| INCY | INCYTE CORP | $23.12B | 18.1x | 21.2% |
| MEDP | Medpace Holdings, Inc. | $18.68B | 43.8x | 20.0% |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $16.49B | — | -0.9% |
| ABSI | Absci Corp | $1.58B | — | -38.2% |
| NRC | NRC HEALTH | $485.1M | 0.4x | -4.0% |
| ONMD | OneMedNet Corp | $279.2M | — | 111.4% |
| MXCT | MAXCYTE, INC. | $144.5M | — | -5.7% |